{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["22(1)"],"submitter":["Papalexi E"],"funding":["Lundbeck Hellas"],"pubmed_abstract":["<h4>Background</h4>Functional recovery is an important treatment goal in major depressive disorder (MDD). This study assessed the real-world effectiveness of vortioxetine in patients with MDD, with particular focus on functioning; dose-response was also assessed.<h4>Methods</h4>This was a non-interventional, prospective, multicenter study conducted in Greece. Adult outpatients with MDD (n = 336) initiating vortioxetine (5-20 mg/day flexible dosing) as treatment for a current major depressive episode were followed for 3 months. Analyses were stratified according to vortioxetine dosage at 3 months: 5-10 mg/day versus 15-20 mg/day. Functioning was assessed using the Sheehan Disability Scale (SDS).<h4>Results</h4>Mean ± standard error SDS total score decreased (improved) from 18.7 ± 0.3 at bas"],"journal":["BMC psychiatry"],"pagination":["548"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9373318"],"repository":["biostudies-literature"],"pubmed_title":["Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects."],"pmcid":["PMC9373318"],"pubmed_authors":["Panagiotidis P","Papalexi E","Karavelas E","Markopoulou M","Balta G","Galanopoulos A","Ettrup A","Kontis D","Vlachos T"],"additional_accession":[]},"is_claimable":false,"name":"Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects.","description":"<h4>Background</h4>Functional recovery is an important treatment goal in major depressive disorder (MDD). This study assessed the real-world effectiveness of vortioxetine in patients with MDD, with particular focus on functioning; dose-response was also assessed.<h4>Methods</h4>This was a non-interventional, prospective, multicenter study conducted in Greece. Adult outpatients with MDD (n = 336) initiating vortioxetine (5-20 mg/day flexible dosing) as treatment for a current major depressive episode were followed for 3 months. Analyses were stratified according to vortioxetine dosage at 3 months: 5-10 mg/day versus 15-20 mg/day. Functioning was assessed using the Sheehan Disability Scale (SDS).<h4>Results</h4>Mean ± standard error SDS total score decreased (improved) from 18.7 ± 0.3 at bas","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2025-04-19T18:56:49.223Z","creation":"2025-04-19T18:56:49.223Z"},"accession":"S-EPMC9373318","cross_references":{"pubmed":["35962369"],"doi":["10.1186/s12888-022-04109-5"]}}